Randomized trial demonstrates enhanced peptide screening and preparation methods for tuna meat hydrolysates, indicating improved ACE inhibition.
Conventional ACE-inhibitory peptide production methods suffer from low yield, suboptimal activity, and extensive optimization. This study introduces DeepAngio, a novel model to address these limitations and enable targeted release. DeepAngio demonstrates high performance in screening (98.80% accuracy, 99.63% precision, and 96.44% specificity) and classification (88.24% accuracy, 86.76% precision, and 95.16% specificity) validated through 10-fold cross-validation. Moreover, DeepAngio facilitated the development of a method for directional preparation of tuna meat hydrolysates with notable ACE inhibitory activity (IC 50, 31.27 ± 0.72 μg/mL). Three novel potent ACE inhibitory peptides were screened from the hydrolysate: LLRP (IC 50, 3.44 ± 0.19 μM), LHWPR (IC 50, 17.67 ± 1.53 μM), and RFLR (IC 50, 42.52 ± 7.50 μM). The peptides inhibited ACE activity via mixed-competitive (LLRP and RFLR) or competitive (LHWPR) mechanisms, forming stable complexes. Spectroscopic and molecular docking analyses revealed distinct binding modes for each peptide.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: